AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.

Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, ...

Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the ...

Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Department of Radiation Oncology and Molecular Radiation Sciences ...

As immunotherapy becomes a cornerstone of cancer treatment, some of the top U.S. cancer centers and health systems are accelerating research efforts to identify the biological mechanisms behind ...

Kassandra Klemenz has pushed through challenges her entire life. Today, she uses that endurance to compete in triathlons.